Calviri, Inc., a biotech startup focused on ending deaths from cancer, announces that Skysong Innovations, the intellectual property management company for Arizona State University (“ASU”), granted Calviri an exclusive license to ASU’s Immunosignature patent portfolio. The portfolio consists of multiple granted and pending patents for the use and optimization of immunosignatures as an antibody-based diagnostic platform in the United States and the rest of the world.
The Immunosignature Technology was invented and originally developed by Stephen Albert Johnston, now CEO of Calviri, and his colleagues at ASU. The platform uses hundreds of thousands of chemically diverse peptides to provide an unbiased profile of an individual’s antibody repertoire. It has been applied to both infectious and chronic diseases in published reports. Initially intended as simply a diagnostic tool to detect disease onset, additional work has shown its potential for measuring disease severity and response to therapies.